Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
about
Linezolid versus vancomycin for skin and soft tissue infectionsLinezolid versus vancomycin for skin and soft tissue infectionsAntibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical woundsLinezolid versus vancomycin for skin and soft tissue infections.Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus.The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infectionsDaptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.Pharmacoeconomics of linezolid.Linezolid for the treatment of drug-resistant infections.Current and novel antibiotics against resistant Gram-positive bacteriaRetrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid.In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.Cost comparison of linezolid versus vancomycin for treatment of complicated skin and skin-structure infection caused by methicillin-resistant Staphylococcus aureus in QuebecClinical management of diabetic foot infection: diagnostics, therapeutics and the future.Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus.Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis.ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.Comment: impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.Optimizing delivery of care for patients with MRSA infection: focus on transitions of care.Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
P2860
Q24186563-936FA71E-A5F4-4F23-9BEB-383346E40108Q24201228-E6390FE5-7211-48E0-BBDF-6F318003CDC7Q24202424-3E84B94A-7445-41F1-8666-2D0293749EDFQ33418740-72158A2B-5634-48B3-AED5-CF609191713AQ34150985-AF68BD93-A9D0-41D7-934A-A01292FBDF00Q34618696-3ABF29F0-8733-463F-AFCF-6C09C23CB43BQ34718540-DFB3DC37-D8F9-49CE-84F2-BCB1B0E0C8DDQ34765976-28AFDE90-159E-4654-AAA9-D5DEC4374BECQ34894133-06310D3C-9B94-4BCB-A0E0-9C8DFA999D6AQ35026521-0407EAFE-B30F-4539-95BB-0B0B80478F44Q35910257-8AAF2DEC-7BB9-46ED-9DAD-9C8A3265D15DQ36558524-B9E30897-E402-476A-AB71-2A1CB9F70AF8Q36684268-19F3C6D3-F031-437A-BA1C-291CF5F1CEB6Q36723810-C17B7927-4532-4D7E-8C0A-E467635171D7Q37196048-5298D05D-0EFF-4CCE-B4DE-EB7F5B08B101Q37331777-A5403DC7-44D7-4F08-A089-D65964198299Q38068456-1A3BBE33-5CFB-4CE1-8413-F137A6A390F3Q38070154-678A1819-3B49-4BAA-A011-042F9BE96035Q38275128-0FA9E5A0-B4B8-4379-99F7-DBC52464AD51Q38283321-2CF5BDD2-A72C-4753-94DB-F03B1C64A0B0Q39816590-95953B0C-0ABB-4B57-B096-BE93EE34828DQ44597214-55A6C39A-0266-4015-AC51-941B69D5658AQ45183500-A4FBC8E6-4C24-40AB-A5BF-4E7A5F1DC962Q46620675-F23FCF7C-C28D-4771-8FD4-1993EA6D57DC
P2860
Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Impact of linezolid on economi ...... in and soft-tissue infections.
@en
Impact of linezolid on economi ...... in and soft-tissue infections.
@nl
type
label
Impact of linezolid on economi ...... in and soft-tissue infections.
@en
Impact of linezolid on economi ...... in and soft-tissue infections.
@nl
prefLabel
Impact of linezolid on economi ...... in and soft-tissue infections.
@en
Impact of linezolid on economi ...... in and soft-tissue infections.
@nl
P2093
P2860
P356
P1476
Impact of linezolid on economi ...... in and soft-tissue infections.
@en
P2093
Kamal Mf Itani
Larry Z Liu
Peggy S McKinnon
Sonja V Sorensen
P2860
P304
P356
10.1345/APH.1G728
P407
P577
2006-05-23T00:00:00Z